ReviewTranslational lung cancer research2020
SV40 and human mesothelioma.
Review in Translational lung cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Construction and validation of a prognostic risk score model for malignant mesothelioma.Discover oncology · 2026Article
- Computational design of a multiepitope vaccine targeting VP1 and VP2 capsid proteins of simian virus 40 (SV40) for enhanced immune activation.Open medicine (Warsaw, Poland) · 2026Article
- Updated practice for detection of viral infections in breeding macaques.Zoological research · 2025Review
- Viral zoonosis and human cancer: a perspective.Infectious agents and cancer · 2025Review
- Article
- Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.Translational lung cancer research · 2025Article
- Health inequality and the global burden of mesothelioma: insights from the global burden of disease study 2021.BMC cancer · 2025Article
- Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).International journal of oncology · 2025Review
- RNA Modifications in Pathogenic Viruses: Existence, Mechanism, and Impacts.Microorganisms · 2024Review
- Stem cell factor and erythropoietin-independent production of cultured reticulocytes.Haematologica · 2024Article
- Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?Current oncology (Toronto, Ont.) · 2024Review
- Malignant Epithelioid Mesothelioma of the Tunica Vaginalis Testis Presenting as Hydrocele in a Kidney Transplant Recipient.Case reports in urology · 2024Article
- Phosphorylation of Human Polyomavirus Large and Small T Antigens: An Ignored Research Field.Viruses · 2023Review
- Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma.Journal of translational medicine · 2023Review
- Current causes of mesothelioma: how has the asbestos ban changed the perspective?Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2023Review
- Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential.Cancers · 2023Article
- Epidemiological Survey and Risk Factor Analysis of 14 Potential Pathogens in Golden Snub-Nosed Monkeys at Shennongjia National Nature Reserve, China.Pathogens (Basel, Switzerland) · 2023Article
- The Role of DNA Viruses in Human Cancer.Cancer informatics · 2023Review
- Unboxing the molecular modalities of mutagens in cancer.Environmental science and pollution research international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simian virus 40 (SV40) is a DNA tumor virus capable of infecting and transforming human mesothelial (HM) cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.